although
number
antivir
agent
evalu
coronavirus
approv
drug
avail
provid
overview
landscap
therapeut
research
conduct
review
regist
clinic
trial
review
current
regist
clinic
trial
perform
registri
includ
chines
chictrorgcn
us
clinicaltrialsgov
databas
identifi
relev
studi
march
th
studi
identifi
clinic
trial
select
data
extract
phase
iv
trial
commonli
report
studi
type
howev
trial
describ
phase
studi
eighti
percent
trial
random
parallel
assign
median
number
plan
inclus
iqr
openlabel
studi
frequent
follow
doubleblind
singl
blind
studi
frequent
assess
therapi
stem
cell
therapi
trial
lopinavirritonavir
chloroquin
umifenovir
hydroxychloroquin
plasma
treatment
favipiravir
methylprednisolon
remdesivir
remdesivir
test
trial
median
iqr
plan
inclus
per
trial
stem
cell
therapi
test
trial
median
iqr
plan
inclus
per
trial
lopinavirritonavir
associ
highest
total
number
plan
inclus
follow
remdesivir
clinic
trial
report
treatment
dose
durat
primari
outcom
clinic
studi
virolog
radiolog
immunolog
three
studi
numer
clinic
trial
regist
sinc
begin
outbreak
howev
number
inform
regard
drug
trial
design
lack
decemb
st
first
suspect
case
epidem
viral
pneumonia
unknown
aetiolog
report
citi
wuhan
china
patient
link
huanan
market
sell
fish
live
anim
januari
th
chines
health
author
world
health
organ
offici
announc
discoveri
novel
coronaviru
current
call
diseas
caus
name
januari
th
declar
epidem
public
health
emerg
intern
concern
pheic
march
th
character
pandem
march
th
case
death
report
world
epidem
uniqu
scale
speed
spread
lack
preexist
scientif
data
import
media
scientif
coverag
scientif
public
health
commun
respond
earli
public
clinic
data
predict
spread
guidanc
effect
contain
alongsid
critic
health
profession
need
find
effect
safe
treatment
patient
infect
although
number
drug
evalu
sarscov
merscov
approv
therapeut
agent
avail
coronavirus
integr
clinic
trial
experiment
therapeut
increasingli
recogn
part
respons
infecti
diseas
outbreak
sinc
ebola
outbreak
west
africa
subsequ
outbreak
democrat
republ
congo
clinic
trial
investig
drug
fulli
integr
epidem
respons
pandem
uniqu
scale
speed
spread
lack
preexist
scientif
data
import
media
scientif
coverag
encourag
develop
clinic
trial
test
therapeut
suggest
number
candid
antivir
agent
test
clinic
trial
concomitantli
numer
clinic
trial
regist
sinc
begin
outbreak
numer
evalu
therapeut
strategi
diseas
epidem
context
crucial
clinician
research
access
rapid
qualiti
inform
clinic
trial
variou
team
around
world
set
result
inform
antivir
agent
use
dose
durat
inclus
exclus
criteria
patient
outcom
evalu
well
design
clinic
trial
believ
essenti
carri
review
earli
phase
clinic
trial
result
even
avail
order
best
inform
team
wish
test
new
therapi
choos
therapeut
candid
design
clinic
trial
review
aim
summar
current
state
regist
clinic
trial
order
studi
design
antivir
agent
investig
detail
administr
outcom
search
perform
clinic
trial
registri
privat
publicli
fund
clinic
trial
worldwid
select
follow
clinic
trial
registri
us
http
clinicaltrialsgov
chines
wwwchictrorgcn
korean
http
crisnihgokrcrisen
iranian
http
wwwirctir
japanes
http
rctportalniphgojpen
european
http
wwwclinicaltrialsregistereu
chose
locat
one
highest
number
case
time
extract
ad
clinic
trial
registri
http
appswhointtrialsearch
intern
standard
randomis
control
trial
number
isrctn
registri
recogn
intern
committe
medic
journal
editor
icmj
first
search
conduct
februari
th
registri
list
captur
studi
regist
novemb
updat
search
conduct
march
th
clinicaltrialsgov
captur
addit
studi
regist
sinc
februari
th
search
strategi
design
identifi
clinic
trial
use
antivir
agent
regist
follow
search
term
use
search
captur
relev
studi
new
coronaviru
novel
coronaviru
data
extract
select
studi
includ
studi
design
sponsorship
popul
outcom
inclusionexclus
criteria
elig
criteria
develop
use
patient
intervent
comparison
outcom
studi
type
pico
framework
inclus
criteria
popul
patient
interventioncompar
antivir
agent
drug
exclud
trial
evalu
tradit
chines
medicin
homeopathi
dietari
supplement
therapeut
strategi
whose
descript
suffici
identifi
specif
drug
outcom
outcom
studi
type
intervent
clinic
trial
exclud
tradit
chines
medicin
homeopathi
expertis
analys
clinic
trial
test
agent
reli
controversi
concept
dietari
supplement
also
exclud
potenti
treat
seem
limit
consid
clinic
trial
plan
includ
patient
sever
diseas
plan
includ
patient
moder
diseas
plan
includ
defin
sever
patient
patient
requir
either
noninvas
ventil
high
flow
oxygen
devic
invas
mechan
ventil
extracorpor
membran
oxygen
ecmo
patient
moder
pneumonia
patient
requir
studi
analys
accord
primari
endpoint
could
clinic
virolog
viral
excret
clinic
sampl
radiolog
imag
result
ctscan
xray
immunolog
cell
count
ifngamma
measur
result
search
identifi
studi
clinic
trial
select
data
extract
review
figur
among
exclud
studi
trial
focu
intervent
interest
eg
tradit
chines
medicin
intervent
clinic
trial
among
includ
clinic
trial
regist
us
clinic
trial
registri
chines
clinic
trial
registri
sponsorship
systemat
report
chines
clinic
trial
registri
prevent
us
accur
analys
privat
public
sponsorship
found
one
trial
plan
inclus
usa
other
recruit
patient
china
data
lack
mani
trial
children
includ
two
clinic
trial
china
one
test
darunavir
cobicistat
without
age
precis
one
human
menstrual
bloodderiv
stem
cell
year
old
six
plan
recruit
patient
age
one
test
lopinavirritonavir
favipiravir
plu
alphainterferon
atom
one
hydroxycholoroquin
one
convalesc
plasma
treatment
one
recombin
human
granulocytecoloni
stimul
factor
gcsf
one
favipiravir
one
human
mesenchym
stem
cell
regist
trial
exclud
pregnant
women
trial
evenli
divid
patient
moder
pneumonia
moder
sever
pneumonia
sever
pneumonia
tabl
phase
iv
trial
commonli
report
studi
type
tabl
phase
ii
phase
iii
howev
regist
trial
describ
phase
studi
regard
blind
found
openlabel
studi
doubleblind
singleblind
vast
major
trial
random
parallel
assign
arm
median
iqr
number
plan
inclus
rang
particip
variou
treatment
evalu
clinic
trial
frequent
evalu
one
describ
tabl
clinic
trial
report
treatment
dose
durat
tabl
detail
combin
therapi
identif
clinic
trial
avail
supplementari
materi
figur
report
number
trial
median
total
number
plan
inclus
per
trial
ten
frequent
therapi
stem
cell
therapi
lopinavirritonavir
chloroquin
phosphat
hydroxychloroquin
favipiravir
umifenovir
plasma
treatment
remdesivir
methylprednisolon
oseltamivir
remdesivir
test
trial
trial
highest
median
number
plan
inclus
per
trial
iqr
end
spectrum
stem
cell
therapi
associ
highest
number
trial
trial
small
median
number
plan
inclus
per
trial
iqr
figur
show
total
number
plan
inclus
number
clinic
trial
ten
frequent
assess
treatment
lopinavirritonavir
associ
highest
total
number
follow
remdesivir
umifenovir
primari
outcom
clinic
studi
tabl
focus
evolut
symptom
time
clinic
recoveri
proport
patient
clinic
improv
deterior
length
hospit
mortal
number
score
use
primari
outcom
ordin
scale
adapt
master
protocol
studi
lung
injuri
score
studi
pneumonia
sever
index
studi
nation
earli
warn
score
news
score
studi
studi
primari
outcom
either
virolog
studi
radiolog
nine
studi
immunolog
three
studi
base
evid
avail
march
th
stem
cell
therapi
lopinavirritonavir
frequent
evalu
candid
therapi
term
number
trial
trial
respect
wherea
remdesivir
associ
highest
median
number
plan
inclus
per
trial
iqr
trial
review
ongo
clinic
trial
assess
treatment
show
import
amount
research
current
conduct
topic
howev
although
number
trial
identifi
high
number
caveat
first
numer
treatment
select
base
variou
level
support
preclin
data
agent
evalu
clinic
trial
shown
vitro
antivir
activ
sometim
includ
coronavirus
lopinavirritonavir
test
clinic
trial
review
combin
shown
vitro
activ
sarscov
sever
studi
appear
activ
merscov
anim
studi
use
agent
treatment
describ
case
report
case
seri
patient
infect
singapor
found
clinic
trial
evalu
hydroxychloroquin
chloroquin
whose
mechan
action
similar
vitro
antivir
activ
chloroquin
known
long
time
describ
number
virus
includ
sarscov
howev
chloroquin
fail
demonstr
benefit
treatment
viral
diseas
influenza
dengu
chikungunya
regard
recent
public
report
activ
chloroquin
anoth
encourag
use
chloroquin
patient
basi
unreport
clinic
result
expert
china
suggest
use
chloroquin
patient
infect
clinic
data
provid
yet
support
announc
remdesivir
evalu
clinic
trial
highest
median
number
plan
inclus
per
trial
studi
vitro
human
airway
epitheli
cell
assay
demonstr
remdesivir
inhibit
replic
coronavirus
includ
merscov
mous
infect
model
remdesivir
therapeut
efficaci
sarscov
merscov
recent
nonhuman
primat
studi
remdesivir
treatment
initi
hour
post
inocul
merscov
provid
clinic
benefit
reduct
clinic
sign
reduc
viru
replic
lung
decreas
presenc
sever
lung
lesion
rational
use
stem
cell
therapi
base
immunomodulatori
properti
could
interest
sever
howev
stem
cellbas
therapi
demonstr
effect
treat
viral
diseas
scientif
background
test
weak
fact
stem
cell
therapi
shown
effect
antivir
diseas
one
frequent
assess
therapi
unexpect
highlight
fact
research
strive
conduct
clinic
trial
promis
candid
accord
vitro
preclin
vivo
scientif
data
second
data
often
lack
regard
studi
design
treatment
assess
dose
durat
restrict
inform
avail
research
potenti
delay
find
success
treatment
third
trial
plan
includ
low
number
patient
reduc
robust
futur
result
clinic
trial
although
number
taken
caution
repres
anticip
number
inclus
trial
actual
number
patient
includ
fourth
primari
outcom
heterogen
clinic
trial
use
clinic
outcom
encourag
diseas
know
associ
viral
clearanc
radiolog
immunolog
evolut
clinic
statu
due
pandem
context
associ
number
clinic
trial
regist
increas
day
day
previou
review
conduct
februari
th
found
clinic
trial
evalu
antivir
agent
drug
review
add
evid
screen
larger
number
clinic
trial
registri
report
studi
design
random
alloc
number
plan
inclus
well
treatment
dose
durat
diseas
sever
primari
outcom
use
import
amount
work
conduct
research
encourag
therapeut
research
new
diseas
howev
care
taken
design
clinic
trial
complic
context
robust
result
need
order
abl
find
appropri
treatment
find
best
agent
rapid
implement
clinic
trial
new
outbreak
challeng
studi
underlin
need
regist
much
detail
possibl
clinic
trial
registri
outbreak
order
inform
develop
futur
trial
scientif
background
support
use
treatment
clear
detail
much
possibl
dose
durat
drug
evalu
well
detail
studi
design
popul
interest
primari
outcom
crucial
element
share
context
epidem
respons
report
much
detail
possibl
key
consist
clinic
trial
enhanc
reproduc
result
especi
studi
often
associ
low
number
plan
inclus
composit
weak
outcom
limit
efficaci
assess
treatment
transpar
consist
crucial
report
clinic
trial
order
improv
statist
power
conduct
exampl
metaanalys
develop
clinic
trial
outbreak
adapt
process
new
evid
produc
impress
rate
review
strategi
alreadi
regist
offici
clinic
registri
clinic
trial
import
asset
research
methodologist
result
might
inform
adapt
exist
clinic
trial
develop
addit
trial
ccbynd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
http
doi
medrxiv
preprint
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
http
doi
medrxiv
preprint
ccbynd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
ad
trial
use
drug
alon
part
combin
therapi
frequent
among
trial
select
defin
sever
patient
patient
requir
either
noninvas
ventil
high
flow
oxygen
devic
invas
mechan
ventil
extracorpor
membran
oxygen
ecmo
patient
moder
pneumonia
patient
requir
note
iv
intraven
sc
subcutan
